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Abstract
Purpose Recent data indicate that extended dosing intervals (EDIs) with lanreotide autogel 120 mg are effective and well-
received among patients with acromegaly who have achieved biochemical control with monthly injections of long-acting
somatostatin analogues (SSAs). We further evaluated the effectiveness of lanreotide autogel 120 mg delivered at EDIs
(>4 weeks) in routine clinical practice.
Methods Cross-sectional, multicentre, observational study conducted to determine the effectiveness—measured by control
of serum insulin-like growth factor 1 (IGF-1)—of lanreotide autogel 120 mg at dosing intervals >4 weeks for ≥6 months in
selected patients with acromegaly treated in routine clinical practice (NCT02807233). Secondary assessments included
control of growth hormone (GH) levels, treatment adherence, patient satisfaction, and quality of life (QoL) using validated
questionnaires (EQ-5D, AcroQoL, and TSQM-9). Patients who received radiotherapy within the last 6 months were
excluded.
Results Among 109 patients evaluated, mean (SD) age was 59.1 (13.2) years. IGF-1 values were normal (mean [SD]: 175.0
[74.5], 95% CI: 160.8 –189.1) in 91.7% of cases and normal in 91.4% of patients without previous radiotherapy treatment
(n= 81). GH levels were ≤2.5 and ≤1 ng/mL, respectively, in 80.6% and 58.3%. Most patients were treated either every 5–6
(57.8%) or 7–8 weeks (38.5%), with 2.8% treated greater than every 8 weeks. The mean AcroQoL score was 63.0 (20.1).
The mean global treatment satisfaction score (TSQM-9) was 75.1 (16.6). Treatment adherence (defined as no missed
injections) was 94.5%.
Conclusion Lanreotide autogel 120 mg at intervals of >4 weeks provided IGF-1 control in more than 90% of patients with
acromegaly. Treatment satisfaction and adherence were good. These findings support use of extended dosing intervals in
patients who have achieved good biochemical control with long-acting SSAs.
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Introduction
Acromegaly is a rare endocrine disorder characterised by
increased production of growth hormone (GH) and insulin-
like growth factor 1 (IGF-1) due to a benign pituitary tumour
[1, 2]. The mainstay of treatment is transsphenoidal surgery
to resect or debulk the pituitary adenoma to normalise GH
secretion [3]. Although surgery is curative in many cases,
~50% of patients require pharmacological therapy, usually
consisting of long-acting somatostatin analogues (SSAs),
generally either lanreotide autogel (Somatuline Depot in the
United States) or octreotide long-acting release (LAR) [3–5].
The main aim of medical treatment is to normalise serum
GH and IGF-1 levels in order to control symptoms and
improve quality of life (QoL).
Conventional SSAs are generally injected on a monthly
basis by healthcare professionals (HCPs) according to the
drug label. However, given the chronic nature of acrome-
galy, the need for frequent visits to the clinic to receive
injections can be burdensome for some patients and may
negatively impact QoL, treatment adherence, and treatment
satisfaction. The development of long-acting SSAs such as
lanreotide autogel, which can be self-administered at home
by the patient or a caregiver, represents a significant
advance in the treatment of acromegaly [6, 7]. In addition, a
growing body of evidence, including an expert consensus
statement [4], suggests that extended dosing intervals
(EDIs) with lanreotide autogel 120 mg of up to 8 weeks
(versus the standard 4-week dosing interval) may be equally
effective in patients who have achieved good biochemical
control with long-acting SSAs [8–10]. The most relevant
benefits of extending the treatment interval are fewer
injections, lower costs, more convenient treatment; in
addition, EDIs and/or dose reductions have both been
shown to reduce the risk of treatment-related side-effects
[3, 4, 9, 11]. Numerous open-label trials have shown that
lanreotide autogel 120 mg administered at dosing intervals
>4 weeks provides comparable biochemical control to
that achieved with standard dosing intervals [4, 9–14].
Nevertheless, more data are needed to evaluate the effec-
tiveness and safety of EDIs in routine clinical practice
[11, 15].
In this context, the aim of the present cross-sectional,
multicentre study was to determine the effectiveness, as
measured by IGF-1 levels, of lanreotide autogel 120 mg
administered at dosing intervals >4 weeks for more than
6 months in patients with acromegaly treated in routine
clinical practice. Secondary aims were to evaluate patient
satisfaction, treatment adherence, and QoL.
Materials and methods
Patients
Inclusion criteria were: (1) adults ≥18 years; (2) confirmed
diagnosis of acromegaly; (3) under treatment with lanreo-
tide autogel 120 mg at dosing intervals >4 weeks for
≥6 months before the study visit; (4) availability of recent
GH and IGF-1 serum levels prior to the study visit; and (5)
signed informed consent form.
Exclusion criteria were: (1) radiotherapy within the last
6 months; (2) active participation in another clinical trial;
(3) presence of physical or mental disorders that could
affect the participant’s capacity to sign the informed consent
form; (4) pregnancy or breastfeeding; and (5) missing data
with regard to the date lanreotide treatment was initiated or
changes in the administration schedule during the prior
6 months.
Design
SOMACROL was a multicentre, cross-sectional, observa-
tional study conducted in hospitals in Spain and Portugal
(NCT02807233). The study included only a single visit
designed to coincide with the patient’s follow-up con-
sultation after ≥6 months of treatment with lanreotide
autogel at dosing intervals >4 weeks. In accordance with
routine clinical practice, the use of EDIs is limited to
patients who have previously achieved clinical and bio-
chemical control under the conventional dosing regimen
(i.e., according to the drug label) [4]. Consequently, all
patients in the present study presented normal IGF-1 levels
at initiation of the EDI. Serum IGF-1 and GH levels were
determined before the study visit.
The primary objective was to determine the effective-
ness (control of serum IGF-1 levels) of lanreotide autogel
120 mg at EDIs (>4 weeks) administered in routine clin-
ical practice in patients with acromegaly after at least
6 months of treatment. Secondary objectives were: (1) to
assess treatment effectiveness based on control of serum
GH levels; (2) to describe the schedule of lanreotide
administration at EDIs in routine clinical practice; and
(3) to evaluate QoL, patient satisfaction, and treatment
adherence.
All patients who met the inclusion criteria and agreed to
participate were enroled in the study after signing the
informed consent form. At the single study visit, all data
required to evaluate the study objectives were recorded on
the electronic case report form (eCRF). At this visit, patients
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completed the following questionnaires: the generic health-
related QoL measure EuroQoL-5D (EQ-5D) [16], the
acromegaly-specific Acromegaly Quality of Life Ques-
tionnaire (AcroQoL) [17], and the Treatment Satisfaction
Questionnaire for Medication (TSQM-9) [18]. Given that
this was an observational study, all participants were treated
in accordance with routine clinical practice and no addi-
tional evaluations or tests, apart from the aforementioned
questionnaires, were requested.
The study was approved by the ethics committees at
the participating hospitals. This study was conducted in
accordance with the Declaration of Helsinki as revised in
2013 [19].
Study variables and outcome measures
The main outcome measure was the serum IGF-1 level
assessed immediately prior to the study visit, which was
classified as normal or high by the treating physician based
on the patient’s age and sex. Serum IGF-1 and GH levels
were determined in local laboratories in accordance with the
standard procedures in place at each participating centre. To
rule out the possible influence of radiotherapy on the main
endpoint, we separately assessed IGF-1 levels for the
patients who did not receive radiotherapy.
Due to normal variations in routine clinical practice, a
variety of dosing regimens (ranging from 5 to 8 weeks)
were used. However, in accordance with the study inclusion
criteria, the dosing interval was >4 weeks in all cases. For
purposes of this study, patients were grouped according to
the dosing intervals (5–6 weeks versus 7–8 weeks). The
following dosing-related variables were evaluated: (1) pro-
portion of patients treated at 5–6 or 7–8 week dosing
intervals; (2) percentage of patients whose dosing regimen
was adjusted <6 months before the study visit; (3) type
(increase or decrease), reason, and date of adjustment in the
dose or administration schedule; and (4) patient preference
for self-administered versus HCP-administered injections.
The EQ-5D consists of a descriptive system to evaluate
five different dimensions of QoL (mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression) and a
self-rated visual analogue scale (VAS) ranging from 0 to
100, in which 0 is the worst and 100 is the best state of
health imaginable [16]. AcroQoL provides a standardised
score ranging from 0 (worst QoL) to 100 (best QoL) [17].
Treatment satisfaction scores using the TSQM-9 range from
0 (lower satisfaction) to 100 (higher satisfaction) [18].
Data on the dose, dose interval, and missed doses during
the 6-month period before the study visit were retro-
spectively obtained from clinical records by the treating
physician, who entered these data on the eCRF. The follow-
ing dosing-related variables were recorded: (1) mean time
(weeks) between injections; (2) number of injections received;
(3) number of missed doses; (4) changes, if any, in the dose
and/or dosing interval. Patients who missed ≥1 injection
during the study period were considered non-adherent.
Statistical analysis
Demographic and clinical data from the eCRFs were
entered in a database created for this purpose. Descriptive
analyses of all variables were performed. Categorical vari-
ables were summarised by absolute frequency (n) and per-
centage (%). Continuous variables were summarised by
measures of central tendency and dispersion: mean, stan-
dard deviation (SD), 95% confidence interval (CI), median,
and range.
The Kolmogorov–Smirnov test was used to determine data
normality. The Student’s t test was used to evaluate normally-
distributed continuous variables while the Mann–Whitney
U test was used to evaluate variables with a non-normal
distribution. Associations between the categorical variables
were assessed with the Chi-square or Fisher’s exact test, as
appropriate. SAS software (version 9.4; SAS Institute, Cary,
NC) was used to perform all statistical analyses. Statistical
significance was set at two-tailed p < 0.05.
The sample size calculation (n= 100) was based on an
estimated prevalence of acromegaly in Spain of 60 cases per
million [20], with 95% CI and 6% precision.
Results
A total of 114 patients were recruited from 38 participating
centres in Spain and a single centre in Portugal. Of these,
five patients were excluded for failure to meet the study
inclusion criteria, resulting in a total of 109 evaluable
patients. The final sample consisted of 62 women (56.9%)
and 47 men (43.1%). The mean age was 59.1 years (SD,
13.2). The sociodemographic and clinical characteristics of
the patients are shown in Table 1.
SSAs were the first-line medical treatment for acrome-
galy or related symptoms in nearly all patients (n= 108;
99%). Most of these patients (n= 73; 67.0%) received
lanreotide autogel 120 mg while 35 patients (32.1%) were
prescribed other formulations of lanreotide (n= 7) or
octreotide (n= 28). One patient received pegvisomant as
first-line therapy (Table 1). In terms of pharmacological
treatments received prior to lanreotide autogel, 36 patients
received a total of 43 treatments (Table 1). Of the 109
evaluable patients, 84 (77.1%) were taking other medica-
tions concomitantly with lanreotide, primarily for the
treatment of cardiovascular (40.9%), gastrointestinal tract,
or metabolic disorders (24.2%). Thirteen patients (11.9%)
received concomitant treatment with cabergoline (n= 8) or
pegvisomant (n= 5).
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Effectiveness
Blood tests performed immediately prior to the study visit
showed mean (SD) IGF-1 values of 175.0 (74.5) μg/L (95%
CI, 160.8–189.1), with 91.7% (95% CI, 86.6–96.9%) of
patients presenting normal IGF-1 values. In the subgroup of
patients who did not receive radiotherapy (n= 81), the
results were similar, with 74 of these 81 patients (91.4%)
presenting normal IGF-1 values.
The mean (SD) GH values were 2.1 (5.1) ng/mL (95%
CI, 1.13–3.08). Overall, 80.6% and 58.3% of the patients,
respectively, presented GH levels ≤2.5 or ≤1 ng/mL (Table
2). The mean time from diagnosis to initiation of EDI was
9.2 years (SD, 8.8; 95% CI: 7.5–10.9). The most common
dosing interval was every 5–6 (57.8%) versus every
7–8 weeks (38.5%); however, in three patients (2.8%), the
dosing interval was greater than 8 weeks.
The study medication was delivered by HCPs in 82.6%
of cases and self-injected in the remaining 17.4% of cases.
Patient preferences for the form of administration yielded
the same result, with 82.6% preferring administration by
an HCP.
Eight patients (7.3%) required treatment adjustment
(change in dose or dosing interval). A total of ten treatment
adjustments were made in these eight patients, as follows:
increase (n= 5) or decrease (n= 3) in the dosing interval,
or dose decrease (n= 2). Thus, 70% of treatment adjust-
ments were performed to extend the dosing interval or to
decrease the dose. The mean (SD) time from treatment
initiation to treatment adjustment was 2.3 (2.5) years
(95% CI, 0.52–4.04).
The most commonly reported issues on the EQ-5D
questionnaire were pain/discomfort (68.5% of the respon-
dents), followed by anxiety/depression (51.9%), and
Table 1 Sociodemographic and clinical characteristicsa
Age, years 59.1 (13.2)
Women, n (%) 62 (56.9%)
Height, cm 165.3 (11.1)
Weight, kg 80.9 (19.1)
BMI, kg/m2 29.4 (5.3)







Time elapsed since diagnosis, years 12.3 (9.6)
Previous treatments (surgery or radiotherapy), n (%)
Surgery alone 53 (48.6)
Radiotherapy alone 5 (4.6)
Surgery+ radiotherapy 23 (21.1)
Neither surgery nor radiotherapy 28 (25.7)
Time elapsed since tumour resection, years 12.8 (9.4)
Time elapsed since radiotherapy, years 17.9 (9.4)
Previous pharmacological treatment, n (%)
Lanreotide (other formulations) 7 (6.4%)
Mean (SD) dose, mg 68.6 (37.6)
Octreotide 28 (25.7%)




aAll data given as mean (SD; standard deviation) unless otherwise
indicated
bSome patients had ≥1 comorbidity
Table 2 IGF-1 and GH levels at the study visit in patients treated with








Normal 100 (91.7%) n/a
High 9 (8.3%)




Time elapsed from the
blood test to the visit, days
109 22.7 (25.4)
GH (ng/mL) 108 (99.1%) 2.1 (5.1)
GH ≤ 2.5 ng/mL
Yes 87 (80.6%) n/a
No 21 (19.4%)
GH ≤ 1.0 ng/mL
Yes 63 (58.3%) n/a
No 45 (41.7%)
GH (ng/mL)
≤1.0 63 (58.3%) n/a
>1 and ≤ 2.5 24 (22.2%)
>2.5 21 (19.4%)
GH level (ng/mL) in patients with normal IGF-1 levels
≤1.0 59 (59.6%) n/a
>1.0–≤2.5 22 (22.2%)
>2.5 18 (18.2%)
n/a not applicable, SD standard deviation, CI confidence intervals
aIGF-1 levels were classified as normal or high by the treating
physician based on the patient’s age and sex
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difficulties with mobility (50.9%), daily activities (46.3%),
or self-care (20.4%) (Fig. 1). The mean (SD) EQ-5D VAS
score was 69.7 (17.9).
The mean (SD) total standardised score on the AcroQoL
questionnaire was 63.0 (20.1), ranging from 3.4 to 96.6
(Fig. 2). The mean scores on the physical and psychological
dimensions of this scale were, respectively, 59.7 (24.5) and
64.9 (20.1). The results of the four standardised dimensions
(physical, psychological, psychological-physical appear-
ance, and psychological-interpersonal relationship) are
shown in Fig. 2.
The mean (SD) scores on the TSQM-9 questionnaire were
as follows: (1) Effectiveness: 70.6 (18.7); (2) Convenience:
69.1 (17.6); and (3) Global satisfaction: 75.1 (16.6).
Treatment adherence
During the 6-month period prior to the study visit, the study
participants received a mean of 3.9 (1.0) injections admi-
nistered at 6 week intervals on average. Based on the eCRF
data, 94.5% (n= 103) were considered treatment adherent
(no missed injections) while 5.5% (n= 6) of patients missed
one or more injections during the study period. Four
patients discontinued treatment due to lack of efficacy
(n= 1) or for unspecified reasons (n= 3). No statistically
significant differences were observed in adherence rates
between the patient group treated every 5–6 weeks versus
those treated every 7–8 weeks (Fig. 3).
Discussion
This study confirms the effectiveness of acromegaly treat-
ment with lanreotide autogel 120 mg at EDIs > 4 weeks for
at least 6 months in routine clinical practice, consistent with
previous reports [4, 9–14]. The most common dosing
intervals in our sample (95.4% of patients) were every
5–6 weeks (57.8%) or every 7–8 weeks (38.5%). Most
patients (91.7%) maintained normal IGF-1 values and GH
levels, which were ≤2.5 and ≤1 ng/mL in 80.6% and 58.3%,
respectively. The results in the subgroup of non-irradiated
patients (n= 81) were virtually identical to those in the
main group, with 91.4% presenting normal IGF-1 levels.
Effectiveness
The effectiveness of the EDI regimen in our sample is
further supported by the finding that only three patients
(2.8%) required a more frequent dosing interval. Indeed,
most of the treatment adjustments (70%) were performed to
Fig. 2 Quality of life. Results of
the Acromegaly Quality of Life
Questionnaire. Higher scores
indicate better quality of life
Fig. 1 Quality of life. Results of the EQ-5D questionnaire. Levels 1–5
indicate, respectively, no, slight, moderate, severe or extreme problems
Fig. 3 Treatment adherence according to dosing interval: 5–6 weeks
versus 7–8 weeks. Patients who missed ≥1 injection were considered
non-adherent
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extend the dosing interval or to decrease the dose. Impor-
tantly, only four patients discontinued treatment, only
one due to “lack of efficacy”. One patient discontinued
treatment—despite reporting symptom improvement—due
to poor gastrointestinal tolerance.
There is a growing body of evidence to support EDIs in
well-selected patients, with numerous open-label studies
showing good symptom control with lanreotide autogel
120 mg administered at EDIs [4, 9–14]. Schopohl et al.
found that switching to lanreotide autogel 120 mg at 6- or 8-
week intervals provided hormonal control and QoL
equivalent to that achieved with 10 or 20 mg of octreotide
LAR administered every 4 weeks [9]. In the LEAD study
[10], more than 75% of patients maintained IGF-1 control at
48 weeks after switching octreotide LAR 10 or 20 mg/
monthly to lanreotide autogel at EDIs, while serum GH
levels remained ≤2.5 ng/mL in 90% of the patients at both
24 and 48 weeks [10]. Our results, in a smaller but real-
world, practice-based multicentre series, were similar.
The results of the LEAD study [10] suggest that the best
candidates for lanreotide 120 mg at EDIs are those patients
who have achieved clinical and biochemical disease control
under the conventional dosing regimen (i.e., every 28 days
with lanreotide autogel 120 mg). Patients who have not
achieved sustained disease control under the conventional
dosing schedule would be unlikely to benefit from EDIs [4].
A prospective, observational study conducted by Orlewska
et al. [11] in Poland in a real-world sample of 143 patients
with acromegaly found that 50% of the patients were receiv-
ing lanreotide autogel 120mg at dosing intervals >4 weeks, a
finding that provides further evidence that the use of EDIs is
becoming increasingly common in routine care [15].
Mode of injection
Potential benefits of lanreotide autogel are the ease of use
due to the delivery system (i.e., pre-filled syringes) and the
ability to self-administer the medication subcutaneously,
which allows for safe and effective administration by HCPs,
but also by the patient or a caregiver [7, 21–23]. In this
real-world study, only 17.4% of the patients used the
self-injection method, with most expressing a preference for
HCP-administered injections. Even so, an important benefit
of lanreotide autogel is that it gives patients the option to
self-inject at home, if they prefer, although more training
could be offered to ensure that patients feel confident in
performing the injection themselves.
Change in dose or dosing interval
Our data show that the EDI was effective in the vast
majority of patients, as only eight patients (7.3%) required a
change in treatment (ten treatment adjustments), most of
which (70%) involved either a further extension of the
dosing interval or a decrease in the dose. Only 30% (three
adjustments) required a more frequent dosing interval.
Quality of life outcomes
In general, QoL in this patient sample was consistent with
previous reports [24]. However, as is to be expected in
patients with acromegaly, the AcroQoL questionnaire identi-
fied several health-related issues, mostly pain and discomfort
(affecting 68.5% of the sample), findings that are in line with
previous reports showing that joint and musculoskeletal-
related pain are present in up to 90% of patients [24].
Although pain is highly relevant to patients with acromegaly
and has a clear negative impact on QoL [25], studies have
shown that psychological status actually has the largest
impact on QoL in this patient population [24, 26]. Anxiety
and depression are common in patients with acromegaly [24]
and the high prevalence of these disorders in our series (>50%
of patients) likely had a negative impact on QoL. Interest-
ingly, although long-acting SSAs provide hormonal control
and improve health-related QoL [23], there is no correlation
between IGF-1 levels and the subjective sense of well-being
reported by patients [24, 26–29].
Treatment satisfaction and adherence
Treatment satisfaction in our study was high, as evidenced
by the mean global satisfaction score (75.1) on the TSQM-9
scale. These findings are consistent with previous reports
demonstrating good patient satisfaction with lanreotide
autogel [11, 29, 30]. Treatment adherence rates were
excellent (94.5%), with only 6 of the 109 patients missing
more than one injection. These findings are in line with
other studies that have evaluated EDIs with lanreotide
autogel, which have reported adherence rates ranging from
90 to 96% [9, 11]. Importantly, there were no significant
differences in adherence between patients treated every
5–6 weeks and those treated every 7–8 weeks.
Study strengths and limitations
The main limitation of this study is the observational
design, with the limitations inherent to this type of study. In
addition, the laboratory tests were not centralised, but
rather performed in local laboratories in accordance with
routine clinical practice. In addition, patients did not
directly compare self-injection to HCP-injection, nor did
they receive training in self-injection methods before
indicating their preferences. The relatively short follow-up
is another limitation, mainly because IGF-1 levels may
remain normal in some patients even after discontinuation
of chronic SSA therapy [31]; consequently, studies with
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longer follow-up are needed to confirm these findings.
While the inclusion of patients treated with radiotherapy
could have influenced the results, our subanalysis shows
that this had no effect on the main study endpoint. Given
that this was a real-world study, the inclusion of patients
treated with radiotherapy (25.7% of the sample) reflects the
reality of routine clinical practice, which is an important
strength of this study. Given the rarity of acromegaly, the
large number of patients (n= 109) is an important strength,
as is the assessment of treatment adherence, patient satis-
faction, and QoL using validated questionnaires.
Conclusions
In this cross-sectional study, lanreotide autogel 120 mg
administered at dosing intervals >4 weeks for at least
6 months was effective in controlling IGF-1 levels in more
than 90% of patients. These findings provide further support
for the use of EDIs with lanreotide autogel 120 mg in patients
with acromegaly who have achieved good biochemical
control with long-acting SSAs. Our data confirm the growing
body of evidence indicating that biochemical control rates
obtained with EDIs in appropriately-selected patients are
equivalent to those obtained with standard dosing intervals.
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